92.98
0.85%
+0.78
After Hours:
92.93
-0.05
-0.05%
BioNTech SE ADR stock is currently priced at $92.98, with a 24-hour trading volume of 382.56K.
It has seen a +0.85% increased in the last 24 hours and a +7.69% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $92.27 pivot point. If it approaches the $93.66 resistance level, significant changes may occur.
Previous Close:
$92.20
Open:
$92
24h Volume:
382.56K
Market Cap:
$22.41B
Revenue:
$2.95B
Net Income/Loss:
$118.10M
P/E Ratio:
8.0583
EPS:
11.5384
Net Cash Flow:
$5.34B
1W Performance:
+1.00%
1M Performance:
+7.69%
6M Performance:
-6.74%
1Y Performance:
-11.95%
BioNTech SE ADR Stock (BNTX) Company Profile
Name
BioNTech SE ADR
Sector
Industry
Phone
49 6131 9084 0
Address
An der Goldgrube 12, Mainz
BioNTech SE ADR Stock (BNTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-05-24 | Initiated | Oppenheimer | Perform |
Dec-01-23 | Downgrade | JP Morgan | Neutral → Underweight |
Oct-16-23 | Downgrade | HSBC Securities | Buy → Hold |
Jul-14-23 | Initiated | HSBC Securities | Buy |
May-17-23 | Upgrade | Redburn | Neutral → Buy |
Dec-15-22 | Upgrade | BofA Securities | Neutral → Buy |
Aug-17-22 | Initiated | Cowen | Market Perform |
Jul-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Jul-06-22 | Resumed | Canaccord Genuity | Buy |
Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
Dec-16-21 | Initiated | Morgan Stanley | Equal-Weight |
Nov-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Oct-22-21 | Initiated | Deutsche Bank | Hold |
Oct-07-21 | Initiated | Jefferies | Hold |
Aug-11-21 | Upgrade | Bryan Garnier | Neutral → Buy |
Jul-19-21 | Resumed | Wolfe Research | Outperform |
Jun-16-21 | Downgrade | Redburn | Neutral → Sell |
May-18-21 | Initiated | Goldman | Neutral |
May-11-21 | Downgrade | Bryan Garnier | Buy → Neutral |
Dec-01-20 | Downgrade | BofA Securities | Buy → Neutral |
Aug-03-20 | Resumed | Berenberg | Buy |
Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
Jun-30-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
May-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
Apr-28-20 | Downgrade | BofA/Merrill | Buy → Neutral |
Mar-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
Mar-09-20 | Initiated | H.C. Wainwright | Neutral |
Jan-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jan-22-20 | Downgrade | UBS | Buy → Neutral |
Nov-05-19 | Initiated | Wolfe Research | Outperform |
Nov-04-19 | Initiated | Berenberg | Buy |
Nov-04-19 | Initiated | BofA/Merrill | Buy |
Nov-04-19 | Initiated | Canaccord Genuity | Buy |
Nov-04-19 | Initiated | JP Morgan | Overweight |
Nov-04-19 | Initiated | SVB Leerink | Outperform |
Nov-04-19 | Initiated | UBS | Buy |
View All
BioNTech SE ADR Stock (BNTX) Latest News
BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch
MarketWatch
BioNTech SE ADR falls Tuesday, underperforms market - MarketWatch
MarketWatch
BioNTech SE ADR rises Monday, outperforms market - MarketWatch
MarketWatch
BioNTech SE Sponsored ADR (BNTX) Stock Sinks As Market Gains: What You Should Know - Yahoo Lifestyle UK
Yahoo Lifestyle UK
BioNTech SE ADR falls Friday, underperforms market - MarketWatch
MarketWatch
BioNTech SE ADR rises Thursday, outperforms market - MarketWatch
MarketWatch
BioNTech SE ADR Stock (BNTX) Financials Data
BioNTech SE ADR (BNTX) Revenue 2024
BNTX reported a revenue (TTM) of $2.95 billion for the quarter ending March 31, 2024, a -76.62% decline year-over-year.
BioNTech SE ADR (BNTX) Net Income 2024
BNTX net income (TTM) was $118.10 million for the quarter ending March 31, 2024, a -98.17% decrease year-over-year.
BioNTech SE ADR (BNTX) Cash Flow 2024
BNTX recorded a free cash flow (TTM) of $5.34 billion for the quarter ending March 31, 2024, a -38.38% decrease year-over-year.
BioNTech SE ADR (BNTX) Earnings per Share 2024
BNTX earnings per share (TTM) was $0.4805 for the quarter ending March 31, 2024, a -98.12% decline year-over-year.
About BioNTech SE ADR
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has a collaboration with Pfizer Inc. to develop vaccines for the coronavirus using its mRNA-based drug development platform; and development and commercialization collaboration with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to advance a vaccine candidate BNT162 for the prevention of COVID-19 infections. The company was founded in 2008 and is headquartered in Mainz, Germany.
Cap:
|
Volume (24h):